Discover and read the best of Twitter Threads about #CadilaHealthCare
Most recents (3)
#CadilaHealthcare Q3 FY22 concall highlights 💊💊
Like & retweet for better reach !
1. Revenues for the quarter were at ₹3655 Cr (1% growth YoY). Excluding COVID related products, growth was 5% YoY.
Like & retweet for better reach !
1. Revenues for the quarter were at ₹3655 Cr (1% growth YoY). Excluding COVID related products, growth was 5% YoY.
EBITDA stood at ₹750 Cr and EBITDA margins were at 20.6% compared to 21.1% in the same quarter last year. PAT for the quarter was at ₹500 Cr.
2. Branded Generics portfolio in India delivered a strong double digit growth. This is the 4th consecutive quarter of strong growth for formulations in India.
In large cap space, CadilaHC looks very interesting.
Generally i restrict to micro caps but new opportunity size looks very interesting which is coupled with existing business.
Stock at all time highs but valuations looks still attractive.
@soicfinance @unseenvalue @KevalAshar
Generally i restrict to micro caps but new opportunity size looks very interesting which is coupled with existing business.
Stock at all time highs but valuations looks still attractive.
@soicfinance @unseenvalue @KevalAshar
Zydu Cadila's new drug *'Virafin',* which is considered successful in the treatment of Covid patients, will soon be available in three districts of UttarPradesh, namely Lucknow, Varanasi and Prayagraj.
#CADILAHC
#CADILAHC
CADILA: MAHARASHTRA MINISTER: ALSO EYEING PURCHASE OF ZYDUS CADILA, J&J VACCINES GOING AHEAD
#CADILAHC
@sandipsabharwal @soicfinance @daytradertelugu @Moneypurseadv @IKSmallcaps @sandeepraop1 @PrasadWakchaure @KevalAshar @Ayush_Gupta03 @AimInvestments
#CADILAHC
@sandipsabharwal @soicfinance @daytradertelugu @Moneypurseadv @IKSmallcaps @sandeepraop1 @PrasadWakchaure @KevalAshar @Ayush_Gupta03 @AimInvestments
I didn't give a long call as it was abreakout. IHowever, the stock was in a trading range. So a target according to measured move is shown. SL according to personal preferences .(trailing/breakeven) 
The reason I don't trade breakouts.
